Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Paquinimod (ABR 25757) 是一种特异性的 S100A8/S100A9 抑制剂,能够减少 SARS-CoV-2 感染小鼠的病毒载量,可用于研究肺炎。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 286 | 现货 | ||
5 mg | ¥ 673 | 现货 | ||
10 mg | ¥ 987 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,630 | 现货 | ||
100 mg | ¥ 4,680 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 792 | 现货 |
产品描述 | Paquinimod (ABR 25757) is a S100A9 inhibitor preventing S100A9 binding to TLR-4. |
体内活性 | Prophylactic treatment of paquinimod reduces synovial activation, osteophyte formation and cartilage damage in experimental OA with high synovial activation (CIOA) and ameliorates pathological effects of S100A9 in OA synovium ex vivo[1].Treatment with paquinimod reduces skin fibrosis measured as reduction of skin thickness and decreased number of myofibroblasts and total hydroxyproline content. The effect on fibrosis was associated with a polarization of macrophages in the skin from a pro-fibrotic M2 to a M1 phenotype. Paquinimod treatment also resulted in a reduced TGFβ-response in the skin and an abrogation of the increased auto-antibody production in this SSc model[1]. |
动物实验 | Two OA mouse models differing in level of synovial activation were treated prophylactic with paquinimod. Synovial thickening, osteophyte size and cartilage damage were measured histologically, using an arbitrary score, adapted Pritzker OARSI score or imaging software, respectively. Human OA synovia were stimulated with S100A9, with or without paquinimod[1].Seven weeks old female B6.Cg-Fbn1(Tsk)/J (Tsk-1) mice were treated with vehicle or paquinimod at the dose of 5 or 25mg/kg/day in the drinking water for 8 weeks. The effect of paquinimod on the level of skin fibrosis and on different subpopulations within the myeloid cell compartment in skin biopsies were evaluated by using histology, immunohistochemisty, a hydroxyproline assay and real-time PCR. Furthermore, the level of IgG in serum from treated animals was also analysed. The statistical analyses were performed using Mann-Whitney nonparametric two tailed rank test[1]. |
别名 | 帕奎莫德, ABR 25757 |
分子量 | 350.41 |
分子式 | C21H22N2O3 |
CAS No. | 248282-01-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (356.72 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8538 mL | 14.269 mL | 28.538 mL | 71.345 mL |
5 mM | 0.5708 mL | 2.8538 mL | 5.7076 mL | 14.269 mL | |
10 mM | 0.2854 mL | 1.4269 mL | 2.8538 mL | 7.1345 mL | |
20 mM | 0.1427 mL | 0.7134 mL | 1.4269 mL | 3.5672 mL | |
50 mM | 0.0571 mL | 0.2854 mL | 0.5708 mL | 1.4269 mL | |
100 mM | 0.0285 mL | 0.1427 mL | 0.2854 mL | 0.7134 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Paquinimod 248282-01-1 Others Inhibitor inhibit 帕奎莫德 ABR25757 ABR-25757 ABR 25757 inhibitor